Targeted imaging of esophageal adenocarcinoma with a near-infrared fluorescent peptide

Xiaoyu Kang1†, Meng Li2†, Lei Liu3†, Shaopeng Liu1, Hao Hu1, Rui Zhang4,5, Siming Ning1, Zuhong Tian1, Yanglin Pan1*, Xuegang Guo1 and Kaichun Wu1

Abstract

Background: Targeted optical imaging offers a noninvasive and accurate method for the early detection of gastrointestinal tumors, especially for flat appearances. In our previous study, a sequence of SNFYMLP (SNF) was identified as a specific peptide to bind to esophageal carcinoma using phage-display technology. This study aimed to evaluate the tumor-targeting efficacy of Cy5.5-conjugated SNF probe for imaging of esophageal carcinoma in vitro and in vivo.

Methods: The SNF-Cy5.5 probe was synthesized and then identified using High Performance Liquid Chromatography (HPLC) and mass spectrometry (MS). Confocal fluorescence imaging and Flow cytometry analysis were performed to evaluate the binding specificity and the receptor binding affinity of SNF-Cy5.5 to OE33. In vivo imaging was performed to evaluate the targeting ability of SNF-Cy5.5 to esophageal carcinoma.

Results: The confocal imaging and flow cytometry analysis showed that SNF-Cy5.5 bound specifically to the plasma membrane of OE33 cells with a high affinity. In vivo, for non-block group, SNF-Cy5.5 probe exhibited rapid OE33 tumor targeting during 24 h p.i. and excellent tumor-to-background contrast at 2 h p.i. For the block group, SNF-Cy5.5 was not observed in the mice after 4 h p.i. Ex vivo imaging also revealed that a higher fluorescent signal intensity value of the tumors was clearly observed in the non-block group than that in the block group (2.6 ± 0.32 × 109 vs. 0.8 ± 0.08 × 109, p < 0.05).

Conclusions: SNF-Cy5.5 was synthesized and characterized with a high efficiency and purity. The higher affinity, specificity, and tumor targeting efficacy of SNF-Cy5.5 were confirmed by in vitro and in vivo tests. SNF-Cy5.5 is a promising optical probe for the imaging of esophageal adenocarcinoma.

Keywords: Esophageal carcinoma, Peptide, Near infrared, Probe

Background

A rapidly increasing trend has presented with regard to the incidence and mortality of esophageal adenocarcinoma (EAC) across the globe for decades, and due to westernized lifestyle, Some developing countries, such as China, embrace same challenge as well [1, 2]. Early diagnosis and treatment of EAC is associated with improved patients’ survival. Opportunistic biopsy using White-light endoscopy has proven to have limited efficacy for diagnosing EAC in routine. In addition, the optical white
imaging is prone to receive false signals from self-absorption and scattering of humans' tissues. Another limitation is the fact that flat lesions are hardly detected due to non-targeted imaging.

Absorption and auto-fluorescence of biological tissues is low in the near-infrared (NIR) spectrum (650–900 nm) [3]. Previous studies have revealed that NIR fluorescence (NIRF) imaging has been used to visualize or measure various biological closely connected with diseases' process in the cellular or molecular level [4–8], which provided more information for us to apply this promising technique to early detection of neoplasm originated from hollow organs. A NIR imaging probe is essential for NIR fluorescent imaging. This probe typically comprised of both targeting moiety and NIR dyes (eg. Cy5.5). The targeting moieties, including nanoparticles, small molecules, peptides, proteins and antibodies or its fragments, could specifically interact with biomarkers in the process of derivation and evolution of tumors. Compared with other moieties, short peptides had the following advantages: easier to be synthesized and modified; rapider blood clearance; increased permeability; lower toxicity and lower immunogenicity [9, 10].

In a previous study, we identified a seven amino acids—peptide sequence, which could specifically bind to human esophageal dysplasia or adenocarcinoma [11]. In our study, we conjugated peptide SNFYMPL with NIRF dye Cy5.5 through the linker (GGGSK) and we evaluated the tumor-targeting efficacy of the probe in vitro and in vivo.

**Methods**

**Synthesis of SNF-Cy5.5**

To maintain the original structure of peptide SNFYMPL and productive conjugation with Cy5.5-NHS, a GGGSK linker was added to the C-terminus of SNFYMPL. The peptide-linker SNFYMPLGGGSK were synthesized through using standard solid-phase fluorenylmethoxycarbonyl chemistry as previously reported [12]. Cy5.5 monofunctional NHS ester was purchased from GE Healthcare (Piscataway, NJ, USA).

Cy5.5 monofunctional NHS ester (0.50 mg, 0.443 µmol, 1 equiv) was dissolved in 200 µl of Dimethyl sulfoxide (DMSO) and mixed with SNF peptide (0.54 mg, 0.443 µmol, 1 equiv) in the dark. Then triethylamine (5 µl) was added to the mixed solution. The reaction mixture was stirred overnight in dark at room temperature. After removal of the solvent, The crude product was dissolved in a solution of 1:1 acetonitrile and H2O and purified by HPLC with a C18 column (25 cm x 10 mm) using a gradient mobile phase beginning from 5% solvent A [0.1% trifluoroacetic acid (TFA) in acetonitrile] and 95% solvent B (0.1% TFA) in water) to 70% solvent A and 30% solvent B at 30 min. Finally, the coloured peak was collected and lyophilized. The ultimate purity of the peptides was confirmed with an analytical C18-column. SNF-Cy5.5 was also analyzed by mass spectrometry.

**Cell culture and condition**

The human-derived esophageal adenocarcinoma cell line OE33 and immortalized epithelial cell line Het-1A were purchased from ATCC (Manassas, VA). OE33 cells were cultured in RPMI 1640 (Gibco) containing 10% FBS (Gibco), and 100 U/mL streptomycin/penicillin. Het-1A cells were cultured in Bronchial Epithelial Cell Growth Medium (BEBM), along with the additives obtained from Lonza/Clonetics Corporation as a kit (Catalog No.CC-3170). All cells were incubated at 37 °C in a 5% CO2 humidified atmosphere.

**Fluorescence imaging**

OE33 and Het-1A cells were grown in 4-chamber slides for 24 h, then the cells were washed 3 times in PBS and fixed with acetone on ice for 15 min. Blocking was performed by adding 10% normal rabbit serum. The cells were then incubated with 10 µmol/L of the SNF-Cy5.5 at dark. In the block group, the cells were incubated with 10 µmol/L of SNF-Cy5.5 and 50 µmol/L of unlabeled SNF peptide. The cells were washed with PBS for 3 times after fluorescently-labeled peptide. 4',6-diamidino-2-phenylindole (DAPI) (Invitrogen, CA, USA) was dropped onto the cell chambers and incubated with cells for 15 min. After a drop of Prolong Gold anti-fade reagent was added onto the slides, the images were acquired using a FLUOVIEW FV1000 laser scanning confocal microscope (Olympus, Tokyo, Japan).

**Flow cytometry analysis**

We also performed flow cytometry to validate Preferential binding of the SNF-Cy5.5 to OE33 cells. Cell triplicates counting about 10^6 were prepared. OE33 cells were the cells were trypsinized, centrifuged at 800 rpm for 5 min, then collected and washed with ice-cold PBS thrice. The cells were then incubated with 10% normal rabbit serum. The cells were then incubated with 10% normal rabbit serum. The cells were then incubated with SNF-Cy5.5, SNF-Cy5.5 with block peptide and PBS at the concentration as previously stated for 30 min on ice. These cells were then washed with ice-cold PBS thrice to clean unspecific binding. Finally, fluorescence-activated cell sorting (FACS) was used to record and analyze the results.

**Animal model**

Athymic female nude male BALB/c mice (4–6 weeks, 20–25 g) were obtained from the Laboratory Animal Center of Fourth Military Medical University (FMMU), with the care and treatment of these animals performed in accordance with FMMU animal protocols. When female athymic nude mice grew until about 4–6 weeks...
old, weighing about 20–25 g, about $5 \times 10^6$ OE33 cells suspended in 200 μL of serum-free RPMI 1640 were injected into the right shoulder of mice. The cells were allowed to grow 2 weeks until tumors’ size was was 5–10 mm. The animal studies were registered and approved by the Animal Welfare and Ethics Committee of Fourth Military Medical School.

**Targeting ability of SNF-Cy5.5 in vivo**

In vivo imaging system (IVIS) Imaging System (IVIS Kinetics, Caliper Life Sciences, Hopkinton, MA, USA), was used to assess the tumor targeting efficacy of the SNF-Cy5.5. A Cy5.5 filter set and identical illumination settings (eg. lamp voltage, filters, f/stop, field of views, binning) were used to acquire all images. The mice in the experimental group ($n = 3$) received a 100 μM of SNF-Cy5.5 tail-intravenously and then exposed to optical imaging of IVIS at various period points after injection. The mice from the block group ($n = 3$) received a 100 μM of SNF-Cy5.5 mixed with unlabeled SNF peptide (1000 μM) as previously described [5]. After IRI fluorescent imaging of the tumor-bearing mice, the mice were euthanized using 100% CO$_2$ in the chamber. Various organs, such as tumor, heart and liver, were excised and subjected to ex vivo fluorescence imaging. The bioluminescent intensities of the regions of interest (ROIs) were measured by Living Image version 4.2 Software. Fluorescent intensity was reported as photons per second per centimeter squared per steradian (p/s/cm$^2$/sr).

**Data analysis**

All the data are described as means ± standard deviation (SD). Statistical analysis was performed using a Student’s $t$ test. To determine tumor contrast, mean fluorescence intensities of the tumor (T) area at the right shoulder of the animal and of the normal tissue (N) at the surrounding tissue were calculated using the ROI function. Dividing T by N yielded the contrast between tumor and normal tissue. Statistical analysis of the data was performed using SPSS 23.0 software (Chicago, IL, USA). If $p$-value < 0.05, Statistical significance was defined.

**Results**

**Synthesis of SNF-Cy5.5**

The chemical molecular structure of SNF-Cy5.5 is presented in Fig. 1. The SNF-Cy5.5 peptide probe was isolated through HPLC purification. As shown in the supplemental Fig. 1, the purity of the main product was

![Schematic structure of the SNF-Cy5.5 conjugate](image-url)
reported as >95%. The retention time of SNF-Cy5.5 on HPLC was 10.9 min. High-resolution mass spectrometry confirmed mass-to-charge ratio (m/z) = 2154.18 for SNF-Cy5.5.

**FACS and fluorescence imaging**

After analysis of FACS results, we found that SNF-Cy5.5 had a stronger binding to OE33 cells (Fig. 2A), Fig. 2B showed that the red fluorescence labeled SNF-Cy5.5 was bound to the cytoplasm of OE33 and not to Het-1a cells. By comparison, in the block group, the red fluorescence is hardly observed for OE33 and Het-1a.

**In vivo fluorescence imaging**

To evaluate the targeting efficacy of SNF-Cy5.5 in vivo, the small animal imaging system was used for imaging of OE-33 tumor-bearing nude mice with SNF-Cy5.5 injection (n=3) or peptide with block (n=3). The static images were acquired at 0.5, 2, 4, 8, 18, and 24 h p.i. in nude mice models (Fig. 3). The SNF-Cy5.5 probe began to present a high tumor-to-background contrast at 0.5 h p.i. and an excellent contrast at 2 h p.i., but the fluorescence intensity of tumor-to-background contrast decreased after 4 h p.i. In the block group, the fluorescence signal could be found at 0.5 h and 2 h p.i. but not observed in the mice after 4 h p.i. Unlabeled SNF peptide significantly reduced OE33 tumor uptake of Cy5.5 SNF compared with the non-block group. The greatest intensity of fluorescence was observed in the hepatic regions from 0.5 to 24 h.

Further evaluation was performed through investigating ex vivo excised organs at 24 h p.i. Figure 4 showed quantified fluorescence intensities of tumor and organs by using ROIs. In the SNF-Cy5.5 group, tumor, liver and kidney had excellent fluorescence intensity compared with that of other organs (Fig. 4A). In the block group, liver and kidney still showed excellent intensity, while the tumor didn’t show it (Fig. 4A). Moreover, the fluorescence intensities of each excised organ were quantified (Fig. 4B). A higher fluorescent signal intensity value of the tumors was clearly observed in the non-block group than that in the block group (2.6 ± 0.32 × 10^9 vs. 0.8 ± 0.08 × 10^9, p < 0.05). No significant differences were
found with regard to the fluorescence intensities of liver, kidney and esophagus.

Discussion

Based on advances in molecular biology and high-tech imaging instruments, molecular imaging has provided more opportunities for noninvasive visualization of abnormal molecules events in living subjects. Molecular imaging has been widely applied in unclear medicine. With the aids of positron emission tomography (PET) and single photon emission computed tomography (SPECT), Molecular Imaging and Precision Medicine has been achieved for the diagnosis of different kinds of tumors [13, 14]. In the recent years, efforts are ongoing to apply optical imaging techniques to molecular imaging in vivo [15–17]. Optical imaging has several advantages over nuclear imaging in the following aspects: reduced side effects, limited facility requirements, lower financial cost and so on [18]. Therefore, the optical imaging has been a major research field in molecular imaging.

Cy5.5 conjugated peptide SNFYMPL is such a biologically active probe in the current study. The linear-chain sequence SNFYMPL was identified through using the technique of phage-display and results showed a high binding affinity to human esophageal adenocarcinoma cells [11], the ELISA and fluorescence staining studies indicate that SNF could be used as a novel marker for human esophageal adenocarcinoma cells. In our previous research, fluorescein isothiocyanate (FITC) conjugated SNF was applied for the early detection of high-grade Barrett’s esophagus and esophageal adenocarcinoma. However, the use of FITC conjugated peptide was only confined to evaluate alterations that arise from the epithelial layer of the tissues, which may leads to the missed diagnose of some flat or invisible lesions [19]. Longer wavelengths, such as NIR would overcome the shortcomings of FITC. Therefore, we synthesized a Cy5.5 conjugated SNF peptide and confirmed it as a novel NIR probe for optical imaging of esophageal adenocarcinoma.

The in vitro testing validated the specificity of SNF-Cy5.5 to esophageal carcinoma cells (OE33 cells). In our previous study [11], SNF peptide selection was performed using phage display (Ph.D.-7, New England Biolabs, Beverly, MA) and a biopanning strategy based on esophageal carcinoma cells (OE33 cells). OE cells were well-validated cells models to investigate the specificity of SNF peptide to esophageal carcinoma cells in our several studies [11, 20]. Flow cytometry analysis showed SNF-Cy5.5 had a stronger binding to esophageal carcinoma (OE33 cells) than blocked SNF-Cy5.5. Besides, in line with the previous peptide concentration of 10 μM for cell staining [19], we used the same concentration peptide concentration in the current study. We demonstrated preferential binding to the plasma membrane of OE33 cells using confocal microscopy. The observation was similar to the other peptides which were found to bind to cell plasma membrane. For instance, Sturm et al. reported that the peptide ASYNYDA identified the cell
surface target as Cyclophilin A (CypA). In the experiment of investigating the mechanism of the specific binding, we found the receptor of binding to SNF peptide was Epithelial cell adhesion molecule (EpCAM) [20]. EpCAM was observed on the cell surfaces of EAC [21], which is consistent to our observation under confocal microscopy.

The tumor targeting efficacy of SNF-Cy5.5 is also validated by in vivo optical imaging. In our current study, we built nude mice model bearing esophageal carcinoma cells (OE33 cells) tumors and validated the tumor targeting efficacy of SNF peptide to esophageal carcinoma cells. In vivo study showed a good uptake of such a low dose of our probe, which suggested a high binding property of SNF-Cy5.5. For the non-block group, the SNF-Cy5.5 presented a fast OE33 tumor targeting (0.5 h p.i.) and continuous high tumor-to-backgroud contrast during 24 h p.i, while, no probe intake was observed after 4 h p.i. for the non-block group, which revealed SNF-Cy5.5 is a target-specific probe. Furthermore, the fluorescence intensities of excised tumors were significantly higher in non-block group than those in blocked group, which is in line with the findings in vivo. It is worthwhile to notice that there is a relatively higher intake of SNF-Cy5.5 by the liver than other organs, including tumors and kidneys. Different short peptides conjugated with Cy5.5 were demonstrated with high intake by the liver [22, 23]. The higher uptake in the liver may be explained by the fact that the hepatic pathway is the main route of excretion.
addition, the kidney was also lighted up, which may suggest the renal pathway is the other important pathway of excretion.

Several tumor-targeted NIRF dyes were developed and investigated as promising probes for esophageal cancer. Chen jing et al. developed QRH*-KSP*-E3-Cy5.5 and showed 88% sensitivity and 87% specificity were found for the detection of either high-grade dysplasia (HGD) or EAC [24]. Lately, KSP-QRH-E3-IRDye800 was developed and the safety of orally administered KSP-QRH-E3-IRDye800 was evaluated for detection of esophageal neoplastic tissues in Phase 1A Study (Identifier: NCT03643068). In addition, Whitley MJ et al. developed LUM015, a novel PEGylated protease-activated far-red fluorescent imaging agent and found this probe could label tumor cells, and residual fluorescence within the tumor bed predicted local recurrence [25]. Currently, intravenously administered LUM015 was also evaluated for detect residual esophageal Cancer in clinical study (Identifier: NCT02584244). Both of the two probes were showed promising application prospects for detection of esophageal cancer. However, the rationales for detection and potential clinical application may be different. KSP-QRH-E3-IRDye800 were specific for human epithelial growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), which were have been found to be high-frequency gene amplified and overexpressed in early esophageal cancer [26, 27]. Thus, the probes of KSP-QRH-E3-IRDye800 and SNF-Cy5.5 were expected to be applied for early detection of early esophageal cancer under infra-red endoscopy, whereas, LUM015 were found to be bind to soft tissue sarcoma, thus, LUM015 was expected to identify microscopic residual disease within the tumor bed could be used to decrease the risk of a positive surgical margin, reduce the rate of re-resection, and tailor adjuvant therapy.

There are several limitations in our research. Firstly, we used an unlabeled SNF peptide as a control to investigate the specificity of SNF peptide to esophageal adenocarcinoma cells based on previous studies [23] and we found SNF-Cy5.5, rather than equal concentration of SNF-Cy5.5 with unlabeled SNF, bound specifically to esophageal adenocarcinoma in vitro and vivo. However, Joshi et al. stated that development of a scrambled peptide was an alternative as a control [28], which inspired us and we will continue to investigate the scramble peptide in further work. Secondly, in addition, due to unproven safety of NIR fluorescent dye Cy5.5, the application of the dye is only limited to the imaging of animal models. indocyanine green (ICG) might be a better alternative. Compared with Cy5.5, ICG has longer wavelengths and established clinical applications [29]. Therefore, it is interesting to investigate SNF peptide labeled with ICG in the future research. Thirdly, though an excellent specific binding of SNF-Cy5.5 has been identified. However, the investigation of the effect of SNF peptide on tumor cell killing was not discussed in our study. So far, compared with specific antibodies with higher binding affinity, short peptides showed a stronger ability in tumor diagnosis application [28]. Short peptides in conjugation with nanoparticles seemed to be promising directions in further applications [30]. Therefore, it required further investigation of the value of SNF peptide on therapeutics at future. Fourthly, fluorescent histopathological staining in vivo study is important to better investigate sensitivity and specificity of the tracer. However, the fluorescent staining was not designed and included in the protocol of in vivo study. Therefore, further research should focus on fluorescent histopathological staining in vivo.

**Conclusion**

Cy5.5-conjugated SNF was synthesized and characterized with a high efficiency and purity. The higher affinity, specificity, and tumor targeting efficacy of SNF-Cy5.5 were confirmed by in vitro and in vivo tests. SNF-Cy5.5 is a promising optical probe for the imaging of esophageal adenocarcinoma.

**Abbreviations**

NIR: Near-infrared; EAC: Esophageal adenocarcinoma; p.i: Post-injection; Cy5.5-SNF: SNF-Cy5.5-SNYMPL; HPLC: High Performance Liquid Chromatography; MS: Mass spectrum; IVS: In vivo imaging system; FACS: Fluorescence-activated cell sorting; BEBM: Bronchial epithelial cell growth medium; DMSO: Dimethyl sulfoxide; DAPI: 4',6-Diamidino-2-phenylindole; TFA: Trifluoroacetic acid; ROI: Region-of-interest; SD: Standard deviation; FITC: Fluorescein isothiocyanate.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12876-021-01840-3.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

KXY, HH and PYL designed the experiment; NSM performed MS and HPLC experiments; KKY and ZR contributed to drafting and revise the manuscript. TZH performed the confocal imaging, LSP did cell culture, flow cytometric analysis and animal imaging. LL, PYL and GXG critically reviewed and revised the manuscript. WKC provided intellectual support; All authors have read and approved the final manuscript.

**Funding**

This work was supported in part by the National Natural Science Foundation of China (82003152, 81370585 and 81570482) and Discipline Promotion Project of Xijing Hospital (XJZT19MJ24). The funding bodies were not involved in the design of this study, in the collection, analysis, and interpretation of the data, or in writing of the manuscript.
Availability of data and materials
All data used to support the findings of this study are included within the article in Figs. 1, 2, 3 and 4 and supplementary material. All datasets on which the conclusions of the manuscript rely are presented in the paper.

Declarations

Ethics approval and consent to participate
The animal studies were registered and approved by the Animal Welfare and Ethics Committee of Fourth Military Medical School (AKY 20170324800, 24 March 2017).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, 127 Changle West Road, Xi’an 710032, Shaanxi, People’s Republic of China. 2 Biotechnology Center, School of Pharmacy, Fourth Military Medical University, Xi’an, Shaanxi, People’s Republic of China. 3 Department of Gastroenterology, Tangdu Hospital of the Fourth Military Medical University, Xi’an, Shaanxi, People’s Republic of China. 4 Department of Critical Care Medicine, Shannxi Provincial Cancer Hospital, Xi’an, Shaanxi, People’s Republic of China. 5 College of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China.

Received: 14 July 2020 Accepted: 8 June 2021
Published online: 12 June 2021

References
1. Edgren G, Adami HO, Weiderpass E, et al. A global assessment of the oesophageal adenocarcinoma epidemic. Gut. 2013;62:1406–14.
2. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–6.
3. Ntziachristos V, Bremer C, Weissleder R. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. J Radiol. 2003;13:195–208.
4. Ma W, Li G, Wang J, et al. In vivo NIRF imaging-guided delivery of a novel NGR-VEGI fusion protein for targeting tumor vasculature. Amino Acids. 2014;46:2721–32.
5. Chen K, Yap LP, Park R, et al. A Cy5.5-labeled phage-displayed peptide probe for near-infrared fluorescence imaging of tumor vasculature in living mice. Amino Acids. 2012;42:1329–37.
6. Cheng Z, Wu Y, Xiong Z, et al. Near-infrared fluorescent RGD peptides for optical imaging of integrin alphabeta3 expression in living mice. Bioconjug Chem. 2005;16:1433–41.
7. Weissleder R, Tung CH, Mahmood U, et al. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol. 1999;17:375–8.
8. Yang Y, Zhang Y, Hong H, et al. In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging. 2011;38:2066–76.
9. Melendez-Alafort L, Muzzio PC, Rosato A. Optical and multimodal peptide-based probes for in vivo molecular imaging. Anticancer Agents Med Chem. 2012;12:476–99.
10. Chen K, Chen X. Design and development of molecular imaging probes. Curr Top Med Chem. 2010;10:1227–36.
11. Li M, Anastassiades CP, Joshi B, et al. Affinity peptide for targeted detection of dysplasia in Barrett’s esophagus. Gastroenterology. 2010;139:1472–80.
12. Thomas R, Chen J, Roudier MM, et al. In vitro binding evaluation of 177Lu-AMBA, a novel 177Lu-labeled GRP-R agonist for systemic radiotherapy in human tissues. Clin Exp Metastasis. 2009;26:105–19.
13. Zukotynski KA, Kim CK. Molecular imaging and precision medicine in uterine and ovarian cancers. PET Clin. 2017;12:393–405.
14. DeRose CM, Hindle E, Kebebew E, et al. Molecular imaging of gastroenteropancreatic neuroendocrine tumors: current status and future directions. J Nucl Med. 2016;57:1949–56.
15. Crane LM, Themelis G, Arts HJ, et al. Intraoperative near-infrared fluorescence imaging for sentinel lymph node detection in vulvar cancer: first clinical results. Gynecol Oncol. 2011;120:291–5.
16. Li Y, Du Y, Liu X, et al. Monitoring tumor targeting and treatment effects of IRDye 800CW and GX1-conjugated polylytic acid nanoparticles encapsulating endorster on glioma by optical molecular imaging. Mol Imaging. 2015;14:356–65.
17. Ding S, Blue RE, Moorefield E, et al. Ex vivo and in vivo noninvasive imaging of epidermal growth factor receptor inhibition on colon tumorogenesis using activatable near-infrared fluorescence probes. Mol Imaging. 2017;16:1536012117729044.
18. van Leeuwen FW, de Jong M, Committee ETTM. Molecular imaging: the emerging role of optical imaging in nuclear medicine. Eur J Nucl Med Mol Imaging. 2014;41:2150–3.
19. Goetz M, Kiesslich R. Advances of endoscopy for gastrointestinal physiology and diseases. Am J Physiol Gastrointest Liver Physiol. 2010;298:G797–806.
20. Ma X, Kang X, He L, et al. Identification of tumor specific peptide as EpCAM ligand and its potential diagnostic and therapeutic clinical application. Mol Pharm. 2019;16:2199–213.
21. Mokrowiecka A, Veits L, Falkeis C, et al. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett’s esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence. Pathol Res Pract. 2017;213:205–9.
22. Zhu D, Qin Y, Wang J, et al. Novel glypican-3-binding peptide for in vivo hepatocellular carcinoma fluorescence imaging. Bioconjug Chem. 2016;27:831–9.
23. Yin J, Hui X, Yao L, et al. Evaluation of Tc-99 m labeled dimeric GX1 peptides for imaging of colorectal cancer vasculature. Mol Imaging Biol. 2015;17:661–70.
24. Chen J, Zhou J, Gao Z, et al. Multiplexed targeting of Barrett’s neoplasia with a heterobivalent ligand: imaging study on mouse xenograft in vivo and human specimens ex vivo. J Med Chem. 2018;61:5323–31.
25. Whitley MJ, Cardona DM, Lazarides AL, et al. A mouse-human phase 1 clinical trial of a protease-activated fluorescence probe for imaging cancer. Sci Transl Med. 2016;8:329ra94.
26. Cronin J, McAdams E, Danikas A, et al. Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett’s esophagus (BE). Am J Gastroenterol. 2011;106:46–56.
27. Dahlberg PS, Jacobson BA, Dahal G, et al. ERBB2 amplifications in esophageal adenocarcinoma. J Natl Cancer Inst. 2005;97:142–6.
28. Cave C, Cunha NN, Walther S, et al. A novel 177Lu-labeled AMBA for systemic radiotherapy in human tissues. Clin Exp Metastasis. 2009;26:105–19.
29. Alander JT, Kaartinen I, Laakso A, et al. A review of indocyanine green fluorescence imaging for sentinel lymph node detection in vulvar cancer: first clinical results. Gynecol Oncol. 2011;120:291–5.
30. Joshi BP, Wang TD. Targeted optical imaging agents in cancer: focus on clinical applications. Contrast Media Mol Imaging. 2018;2018:2015237.
31. Alander JT, Kaartinen I, Laakso A, et al. Review of indocyanine green fluorescence imaging in surgery. Int J Biomed Imaging. 2012;2012:940585.
32. Feng S, Zhou J, Li Z, et al. Sorafenib encapsulated in nanocarrier functionalized with glypican-3 specific peptide for targeted therapy of hepatocellular carcinoma. Colloids Surf B Biointerfaces. 2019;184:110498.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.